Organisation paid for research Program year 2025 Source: CMS Open Payments

Biofortis Inc

Neither a doctor nor a teaching hospital

Research payments

$357,915

42 payments

Through program year 2025, Biofortis Inc is reported as receiving $357,915 in research payments, across 42 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$5,453	1
2024	Research	$5,047	1
2023	Research	$8,168	2
2022	Research	$12,277	9
2021	Research	$115,661	10
2020	Research	$67,868	16
2019	Research	$143,442	3

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $308,962 10 payments
AbbVie, Inc. $30,505 29 payments
Novartis Pharmaceuticals Corporation $18,448 3 payments

Studies the money was for Research payments · program years 2019–2025

FOURIER OLE (Ph 4) $198,038 8 payments
20130295-FOURIER OLE (Ph 4) $110,923 2 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $18,448 3 payments
M16-100 $13,271 11 payments
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $8,416 8 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $4,738 8 payments
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) $4,080 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.